Form 8-K - Current report:
SEC Accession No. 0001213900-25-035640
Filing Date
2025-04-25
Accepted
2025-04-25 17:02:33
Documents
15
Period of Report
2025-04-23
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0239405-8k_pasithea.htm   iXBRL 8-K 33730
2 LETTER FROM MARCUM DATED APRIL 23, 2025 ea023940501ex16-1_pasithea.htm EX-16.1 3712
  Complete submission text file 0001213900-25-035640.txt   259378

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE ktta-20250423.xsd EX-101.SCH 3809
4 XBRL DEFINITION FILE ktta-20250423_def.xml EX-101.DEF 26680
5 XBRL LABEL FILE ktta-20250423_lab.xml EX-101.LAB 36818
6 XBRL PRESENTATION FILE ktta-20250423_pre.xml EX-101.PRE 25304
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0239405-8k_pasithea_htm.xml XML 5935
Mailing Address 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139
Business Address 1111 LINCOLN ROAD, SUITE 500 MIAMI BEACH FL 33139 (702) 514-4174
Pasithea Therapeutics Corp. (Filer) CIK: 0001841330 (see all company filings)

EIN.: 851591963 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40804 | Film No.: 25875078
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)